Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA
Executive Summary
An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings
You may also be interested in...
Mandatory FDA Review Of Pivotal Trial Protocols Urged In JAMA
Dartmouth researchers say that although FDA recommendations can strengthen study designs and improve outcome measures, sponsors often don’t follow agency’s advice or don’t even seek input in Phase III design.
Mandatory FDA Review Of Pivotal Trial Protocols Urged In JAMA
Dartmouth researchers say that although FDA recommendations can strengthen study designs and improve outcome measures, sponsors often don’t follow agency’s advice or don’t even seek input in Phase III design.
Learning From Its Successes? FDA Wants Feedback On All First-Cycle Actions For Assessment Program
Interviews with all sponsors that receive a first-cycle action, approvals as well as other outcomes, under PDUFA V’s new NME and original BLA review program will help FDA assess the program’s success.